< Back to latest news & events

News

EPO Enlarged Board of Appeal decision G4/19 – a European patent application can be refused by reason of the prohibition on double patenting

June 2021

The European Patent Office today confirmed in Decision G4/19 of the Enlarged board of Appeal that a European patent application can be refused for ‘double patenting’.  Such a refusal can be made even absent the European Patent Convention having an explicit double patenting provision.

The claiming of the same subject matter in two applications having the same filing or priority date to the same Applicant is referred to as double patenting.  The European Patent Convention does not contain an explicit prohibition against this practice. However, previous decisions against double patenting have relied upon a reference to general principles of patent law in EPC Contracting States embodied in Article 125 EPC.  For example, Section 18(5) of the UK Patents Act provides such an explicit double patenting provision.  It was argued that the double patenting provision embodied in Article 125 EPC only prevented double patenting in the case of applications filed on the same day or between a divisional application and its parent.

The Enlarged Board of Appeal confirmed that Article 125 EPC compelled the EPO to refuse applications for double patenting by taking into account national law of Contracting States.  Furthermore, the Enlarged Board found that double patenting is also prohibited in the case of internal priority i.e. where two applications benefit from the same priority and claim the same subject matter.

It is worth pointing out that the EPO only construes the probation on double patenting narrowly in order to prevent two patents claiming the same identical subject matter.  Therefore, where differences exist between the claims, the double patenting prohibition should not apply.

This article was prepared by HGF Partner Chris Benson. If you would like further advice on this or any other matter, please contact Chris. Alternatively, you can contact your usual HGF representative or visit our Contact page to get in touch with your nearest HGF office.

Latest updates

The EPO Board of Appeal comments on the scope of the morality exclusion from patentability

The recent decision, T1553/22 of the Board of Appeal required the Board to consider the scope of the exclusions from patentability under Article 53(a) EPC. The invention in this case …

Read article

WIPR Diversity Top 100 2025

HGF’s European Patent Attorney Alexandra Wood has been listed in World IP Review’s (WIPR) Diversity Top 100 2025 World IP Review’s Diversity in IP listings 2025 recognises and celebrates people …

Read article

INTA 2025 Annual Meeting Live

The HGF European team will be attending the INTA Annual Meeting Live, which will take place on 17th-21st May in San Diego, US. The conference will connect some of the …

Read article

HGF wins big at the Managing IP EMEA Awards Ceremony 2025

The Annual Managing IP Awards: EMEA Awards 2025 were announced last night, and HGF are proud to have won 7 awards. The Managing IP Awards are highly recognised and respected …

Read article

Plant Patent Infringement in the US Relies on Evidence of Asexual Reproduction

A recent case in the US District Court for the Northern District of Texas (Dallas Division) once again highlights how important the initial pleadings and evidence in patent infringement cases …

Read article

Exam Success at HGF!

HGF is pleased to announce that several of our attorneys have passed their UK Advanced Patent exams! In no specific order, we would like to say well done and a …

Read article

IP Ingredients: How food companies are using IP to stay ahead of the GLP-1 curve

The impact of GLP-1 on the food and beverage sector GLP-1 agonists, best-known under the brand names Ozempic® and Wegovy®, are medicines used to treat type 2 diabetes and obesity. …

Read article